Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM19D7G)

• Drug Name: PMID22686657C(R)-26 Drug Info
• Synonyms: GTPL6535; BDBM50392215

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 60148519
  TTD Drug ID: DM19D7G

Molecule-Related Drug Atlas

Drug(s) Targeting Cathepsin S (CTSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7625	DMDGPKS	Autoimmune disease	4A40-4A45	Phase 2	[2]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[3]
VBY- 891	DMTKPH4	Autoimmune diabetes	5A10	Phase 1	[4]
VBY- 036	DMULRYC	Neuropathic pain	8E43.0	Phase 1	[5]
VBY-129	DM4YIWK	Autoimmune diabetes	5A10	Phase 1	[6]
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[7]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[7]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[7]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[8]
PMID27998201-Compound-17	DMAZVHJ	Hair loss	ED70	Patented	[7]

Drug(s) Targeting Cathepsin F (CTSF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[7]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[7]
WRR-99	DM8ZA6K	Discovery agent	N.A.	Investigative	[9]
Benzoyl-Arginine-Alanine-Methyl Ketone	DMC7TNF	Discovery agent	N.A.	Investigative	[9]
WRR-112	DMP761U	Discovery agent	N.A.	Investigative	[9]
HOMOPHENYLALANINYLMETHANE	DMVBTHA	Discovery agent	N.A.	Investigative	[10]
BENZOYL-TYROSINE-ALANINE-METHYL KETONE	DMIRD8S	Discovery agent	N.A.	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cathepsin F (CTSF)	TTJOKD1	CATF_HUMAN	Inhibitor	[1]
Cathepsin S (CTSS)	TTUMQVO	CATS_HUMAN	Inhibitor	[1]

References

• [1] Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F. J Med Chem. 2012 Jun 28;55(12):5982-6.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
• [5] Clinical pipeline report, company report or official report of ViroBay.
• [6] Clinical pipeline report, company report or official report of ViroBay.
• [7] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [8] An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [10] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.